(Q37652537)

21 August 2017

1 reference

title

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq (English)

1 reference

21 August 2017

1 reference

1 reference

1

Max Ciarlet

1 reference

21 August 2017

Florian Schödel

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

27 Suppl 6

1 reference

21 August 2017

page(s)

G72-81

1 reference

Rotavirus and severe childhood diarrhea

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Global Illness and Deaths Caused by Rotavirus Disease in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

The impact of rotavirus gastroenteritis on the family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Evidence of interspecies transmission and reassortment among avian group A rotaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Molecular analysis of the VP7 gene of pheasant rotaviruses identifies a new genotype, designated G23.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Failure of live, attenuated oral rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Sequence analysis of the VP4, VP6, VP7, and NSP4 gene products of the bovine rotavirus WC3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Prolonged efficacy of rhesus rotavirus vaccine in Swedish children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Genomic characterization of a novel group A lamb rotavirus isolated in Zaragoza, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Early phase II trial of human rotavirus vaccine candidate RV3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Rotavirus infection in infants as protection against subsequent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

Cost-effectiveness analysis of a rotavirus immunization program for the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

inferred from DOI database lookup

Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

inferred from DOI database lookup

Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2009.09.107

1 reference

release_tonbmm4uefatha3guqwhxkwaie

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tonbmm4uefatha3guqwhxkwaie

24 November 2022

mapped directly with Wikidata item

1 reference